Transcript: Which HIV Meds Cause Lipoatrophy?

Transcript: Beyond Condoms: Medical Approaches For Prevention

Transcript: Simple Test Eliminates Abacavir Risk

Transcript: Are We Starting Treatment Early Enough?

Transcript: The Latest on Lipo: Advances & Setbacks

Prezista Superior to Kaletra for Treatment-Experienced Patients
Preliminary results from a major clinical trial have demonstrated that Prezista plus Norvir is more effective than Kaletra in treatment-experienced HIV-positive patients.

NNRTI Etravirine Effective for Treatment-Experienced Patients
Studies reviewed at the fourth IAS Conference in Sydney indicate that Tibotec's NNRTI etravirine, combined with the company's PI Prezista, is safe and effective for treatment-experienced HIV-positive patients.

PRO 140 Shows Promise in Single-Dose Study
Researchers have reported encouraging results from an early study of PRO 140, an experimental HIV entry inhibitor.

FDA to Reevaluate MSM Blood Donation Ban Following Criticism

CDC: Nearly 50% of Black Women Ages 14 to 49 Have Genital Herpes

Study: Circumcision Might Not Prevent HIV Transmission Among MSM

Chemical in Bananas May Prevent and Treat HIV
A chemical in bananas has been found to inhibit HIV, according to research findings from a University of Michigan Medical School published in the March 19 issue of the Journal of Biological Chemistry. According to the study authors, this may lead to the development of inexpensive microbicides to prevent HIV transmission and, quite possibly, novel compounds to treat the disease.

Sexual Problems More Common Among HIV-Positive Women
Women living with HIV are significantly more likely to experience sexual problems compared with those not living with the virus, according to new results from the Women's Interagency HIV Study (WIHS) published online ahead of print by the Journal of Acquired Immune Deficiency Syndromes (JAIDS).

Replication Capacity: An Additional Measure of HIV Disease Progression?
HIV’s replication capacity (RC), a measurement of the virus’s fitness, may be useful for people living with HIV and their health care providers in figuring out how quickly HIV disease will progress, according to new data published in the April 1 issue of the Journal of Acquired Immune Deficiency Syndromes (JAIDS). The study results show that untreated people living with HIV with lower, compared with higher, RC had a slower progression to a CD4 cell count below 350 cells—the widely accepted threshold for starting antiretroviral (ARV) therapy.

Treatment Interruptions “Particularly Hazardous” for Those Coinfected With Hep B
Interrupting antiretroviral (ARV) therapy may be “particularly hazardous” for people living with HIV and chronic hepatitis B virus (HBV) infection, according to data from the Strategies for the Management of Antiretroviral Therapy (SMART) study published online by the journal AIDS. Increases in HBV viral load and accelerated immune deficiency were documented among coinfected individuals partaking in structured drug holidays in the study.

HIV and the Brain: Part 2
At the 17th Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco—David Evans speaks with Scott Letendre, MD, from the University of California in San Diego, about the relationship of HIV levels in the brain versus the blood, and what that might mean for treating HIV.

New Treatments for HIV: Part 1
At the 17th Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco—Tim Horn speaks with David Hardy, MD, from Cedars Sinai Medical Center in Los Angeles, about new HIV treatments—including the drug blood level-booster, cobicistat, and the new integrase inhibitor, elvitegravir. Part 1 of a 2-part video.

Puckering Up for AIDS Awareness
Pop stars Lady Gaga and Cyndi Lauper are helping the M·A·C AIDS Fund (MAF) educate women and girls about HIV/AIDS. MAF executive director Nancy Mahon tells POZ about M·A·C Cosmetics’ latest Viva Glam campaign.